Next-generation sequencing (NGS) and biomarker testing now anchor non-small cell lung cancer (NSCLC) care alongside immunotherapy and targeted therapies. To make testing feasible, clinicians are using higher-yield sampling methods (eg, navigational bronchoscopy, endoscopic ultrasound) and tighter multidisciplinary coordination with radiology and pulmonology so oncologists have results at the first visit. PD-L1 remains a key guide but can vary by assay, so results are interpreted in context. Comprehensive upfront diagnosis with timely NGS (often in ~5–10 days) is stressed for stages IB to IIIA, with short-term bridging therapy acceptable only when clinically urgent.
Lung cancer screening with low-dose CT has been approved in the United States since 2015, yet uptake lags. Evidence such as the NELSON trial shows screening reduces lung cancer mortality, but broad implementation requires primary-care ordering, workflow support, and solutions to radiologist capacity—an area where AI triage and reading support may help. Overall, early, complete biomarker testing plus better screening infrastructure are critical to getting patients to the appropriate treatment on time.
Reference: Doherty K. Widespread NGS Accessibility Is Crucial to Offering Ideal Treatment in NSCLC. OncLive. Published January 14, 2026. Accessed January 20, 2026. https://www.onclive.com/view/widespread-ngs-accessibility-is-crucial-to-offering-ideal-treatment-in-nsclc
